BioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will report its Q3 2020 financial results on November 5, 2020, before U.S. market open. A conference call and webcast will take place at 8:30 AM ET on the same day to discuss the results and update on business operations. BDSI focuses on chronic conditions and leverages its proprietary BEMA® technology to address serious medical needs, including chronic pain and opioid-induced constipation.
- BDSI's proprietary BioErodible MucoAdhesive (BEMA®) technology aims to fulfill unmet medical needs.
- None.
RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its third quarter 2020 financial results before the open of the U.S. financial markets on Thursday, November 5, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Thursday, November 5, 2020 |
| Time: | 8:30 AM Eastern Time |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13710272 |
| Webcast: | http://public.viavid.com/index.php?id=141502 |
About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
© 2020 BioDelivery Sciences International, Inc. All rights reserved.
Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
FAQ
When will BioDelivery Sciences report its Q3 2020 financial results?
What time is the conference call for BDSI's Q3 2020 results?
How can I access BDSI's conference call and webcast?
What is the focus of BioDelivery Sciences International?
